In addition, for GeparSixto (GBG 66), it was found that the pCR rate in patients with triple-negative breast cancer in a general group (regardless of BRCA1 or -2 status) was higher than that in a carboplatin-treated group (RR: 1.87; 95% CI: 1.17–2, 97; p = 0.009), with 56.8% (83 of 146 patients) in the carboplatin group and 41.4% (60 of 145) in the carboplatin-free group. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.